WHO Medicines Access Platform ‘Compromised’ By Industry Involvement
Executive Summary
A new World Health Organization platform for discussing access to medicines could be too heavily influenced by the pharmaceutical industry, says the NGO Health Action International. The European industry federation EFPIA disagrees.
You may also be interested in...
Stakeholders Must ‘Fully Engage’ If WHO’s Medicines Access Platform Is To Succeed
Delegates at the European Health Forum Gastein outlined the challenges facing an international effort to improve access to costly new medicines across the World Health Organization’s European region, insisting that the key issues had to be addressed “collectively” and without “finger pointing.”
New WHO Access Platform Could Mean Tiered Pricing In Europe
New platform for finding solutions to increase access to expensive medicines should ensure sustainability of health care systems and pharmaceutical industry and could include tiered pricing models.
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.